DMT Entities

UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: Cash on hand as of May 31 was approx. $9.9 (CA$13.2) million, an almost 30% quarterly outflow as compared to the $14 million held on Feb. 28...

UK-based biotech firm Small Pharma Inc. (OTCQB: DMTTF) shared its financial outcomes for the fiscal year ended Feb. 28, plus pipeline updates.  Highlights: Total cash of $13.9 (CA$18.5) million as of Feb. 28, 2023 compared to $30.6 million held on the same date in 2022. Yearly R&D...

U.K.-based short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) has been working hard on securing a proprietary IP throughout North America, Australasia and Europe. CEO George Tziras says the team has made progress in 2023 to further strengthen the company’s IP position in key...

Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing three-part Phase 1 trial evaluating both intravenous DMT and CYB004 in healthy volunteers....

Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug CYB004. While the trial evaluates safety and efficacy of escalating doses of DMT and CYB004 in healthy...

Short-acting psychedelics company Small Pharma Inc. (OTCQB: DMTTF) has shown positive outcomes from a six-month follow-up of its Phase 2a clinical trial of proprietary DMT compound SPL026 for the treatment of Major Depressive Disorder (MDD.)  The trial assessed the safety...

Canadian biopharma company Algernon Pharmaceuticals Inc. (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience (AGN Neuro) completed dosing the second cohort of its Phase 1 study on the company’s proprietary IV formulation of DMT, AP-188. It is now moving forward with the final cohort...

Short-acting psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) shared positive outcomes from its Phase 2a study of SPL026, the first placebo-controlled trial of the DMT-based short-duration psychedelic compound for the treatment of Major Depressive Disorder (MDD).  The trial...

Specialty R&D psychedelics company PharmaDrug Inc. (OTCQB: LMLLF) has inked a research collaboration agreement with PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) to evaluate the delivery of DMT through PharmaTher's microneedle patch technology. PharmaDrug has said that the DMT...

Biopharma company Algernon Pharmaceuticals (OTCQB: AGNPF) has launched a new clinical research program via a subsidiary. The goal is to treat Traumatic Brain Injury (TBI) with the company’s proprietary DMT compound AP-188.  Algernon NeuroScience, or AGN Neuro, has an ongoing stroke...

Algernon Pharmaceuticals (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience has completed the first cohort in its Phase 1 clinical study of a DMT compound. There were no observed safety or tolerability issues, the company stated. Algernon is "breaking new ground in this study in terms of...

Psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) has dosed the first subject in its first-in-human clinical trial assessing proprietary DMT drug SPL028 paired with supportive therapy. Conducted at MAC Clinical Research in Manchester (UK), the randomized, blinded, placebo-controlled,...

Cybin Inc. (NYSE: CYBN) has shared its unaudited financial results for the third quarter that ended Dec. 31, 2022. The company held total cash of $16.9 (CA$22.5) million as of Dec. 31, 2022, and $15 million as of Feb. 14, 2023. The quarter’s net loss was $8 million compared to $12.9 million...

After the positive results provided by its clinical trial assessing novel DMT’s effects on patients with Major Depressive Disorder (MDD), psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) is updating its IP portfolio following the United States Patent and Trademark Office (USPTO)...

Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major Depressive Disorder (MDD). The trial, which was aimed to assess the efficacy and...